Amarin Corp PLC (AMRN) stock

AMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 10/3063% above fair value

$11.38−0.29 (-2.49%)

Close on Nov 13, 2026Market cap $251.55MP/E –Yield –

Amarin EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Amarin's EV/EBITDA was 58.3× on Apr 29, 2022.

Period	Period end	Value	Change (pts)
2022	Apr 29, 2022	58.3×	−501.0
2021	Dec 31, 2021	559.3×	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AMRN.

Revenue growth-22.3% · median 6.8%

Gross margin40.9% · median 78.9%

Operating margin-18.2% · median 10.1%

Net margin-10.9% · median -1.2%

Advertisement
300 × 250

See a number that looks wrong?